Journal Article

Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature

D. Pastorelli, G. Cartei, F. Zustovich, F. Marchese, G. Artioli, S. Zovato, S. Binato, R. Ceravolo, S. Cingarlini, F. Salmaso, M. Mattiazzi, C. Sanavio, F. Farinati, G. Zanus and U. Cillo

in Annals of Oncology

Published on behalf of European Society for Medical Oncology

Volume 17, issue suppl_5, pages v153-v157
Published in print May 2006 | ISSN: 0923-7534
Published online May 2006 | e-ISSN: 1569-8041 | DOI: http://dx.doi.org/10.1093/annonc/mdj972
Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature

Show Summary Details

Preview

Background: Advanced biliary tract cancers have a poor prognosis. Gemcitabine (G) as a single agent or in combination represents an active treatment option. Systemic chemotherapy in hepatocellular carcinoma represents a palliative treatment. Gemcitabine in combination with Liposomal Doxorubicin (LD) may represent an active treatment option.

Patients and methods: Clinical trials for biliary and hepatic carcinoma have been reviewed.

Results: We obtained RC (1 pt), RP (4 pts), SD (8 pts) and seven pts had PD (RR 25% and SD 40%). Our chemotherapy regimen was Gemcitabine 1000 mg/m2 d 1 and 8, Liposomal Doxorubicin 30 mg d 1, q 28. Patients were 21 (17 M), aged 44 to 78 (median 63 yrs). Only in 8 pts we observed G 3–4 haematological toxicity, thrombocytopenia and neutropenia (7 G3, 1 G4).

Keywords: biliary tract cancers; chemotherapy; hepatocellular carcinoma

Journal Article.  0 words. 

Subjects: Medical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.